Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.
Clinical trial NCT06272799 · RECRUITING
Trial details
- NCT number
- NCT06272799
- Sponsor
- Regina Elena Cancer Institute
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2022-09-20
- Primary completion
- 2024-09-20
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.